Omeros (OMER) Non-Current Assets (2010 - 2026)
Omeros recorded quarterly Non-Current Assets of $105.8 million in Q1 2026, down 3.77% quarter-over-quarter from $110.0 million in Q4 2025, and down 23.86% year-over-year from $139.0 million in Q1 2025.
Omeros' Non-Current Assets history runs 17 years deep, the most recent figure standing at $105.8 million for Q1 2026.
- In Q1 2026, Non-Current Assets fell 23.86% year-over-year to $105.8 million; the TTM figure through Mar 2026 stood at $460.6 million (down 21.09% YoY), while the FY2025 annual figure was $110.0 million, down 23.08% from the prior year.
- Non-Current Assets came in at $105.8 million for Q1 2026 at Omeros, down from $110.0 million in the prior quarter.
- In the past five years, Non-Current Assets ranged from a high of $169.0 million in Q3 2022 to a low of $105.8 million in Q1 2026.
- A 5-year average of $142.0 million and a median of $143.1 million in 2023 frame the typical range for Non-Current Assets.
- Across the five-year window, Non-Current Assets surged 449.14% in 2022 and decreased 23.86% in 2026, its largest moves.
- Omeros' Non-Current Assets stood at $147.7 million in 2022, then climbed by 8.55% to $160.4 million in 2023, then slipped by 10.86% to $143.0 million in 2024, then slipped by 23.08% to $110.0 million in 2025, then fell by 3.77% to $105.8 million in 2026.
- According to Business Quant data, Non-Current Assets over the past three periods registered $105.8 million, $110.0 million, and $113.9 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 4.56 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | 62,953.78 |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 486.60 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | 5.83 Mn |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 30.30 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 14.75 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 22.66 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 910.24 Mn |
| 10 | Omeros | 772.03 Mn | 636.71 Mn | 9.31 Mn | 105.82 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 105.82 Mn |
| Dec 31, 2025 | 109.97 Mn |
| Sep 30, 2025 | 113.90 Mn |
| Jun 30, 2025 | 130.92 Mn |
| Mar 31, 2025 | 138.98 Mn |
| Dec 31, 2024 | 142.96 Mn |
| Sep 30, 2024 | 148.41 Mn |
| Jun 30, 2024 | 153.38 Mn |
| Mar 31, 2024 | 156.53 Mn |
| Dec 31, 2023 | 160.37 Mn |
| Sep 30, 2023 | 141.73 Mn |
| Jun 30, 2023 | 138.86 Mn |
| Mar 31, 2023 | 143.10 Mn |
| Dec 31, 2022 | 147.73 Mn |
| Sep 30, 2022 | 169.01 Mn |
| Jun 30, 2022 | 152.92 Mn |
| Mar 31, 2022 | 159.04 Mn |
| Dec 31, 2021 | 171.31 Mn |
| Sep 30, 2021 | 32.08 Mn |
| Jun 30, 2021 | 32.99 Mn |
| Mar 31, 2021 | 28.96 Mn |
| Dec 31, 2020 | 29.76 Mn |
| Sep 30, 2020 | 31.09 Mn |
| Jun 30, 2020 | 31.76 Mn |
| Mar 31, 2020 | 32.60 Mn |
| Dec 31, 2019 | 33.22 Mn |
| Sep 30, 2019 | 27.46 Mn |
| Jun 30, 2019 | 23.82 Mn |
| Mar 31, 2019 | 24.38 Mn |
| Dec 31, 2018 | 6.07 Mn |
| Sep 30, 2018 | 9.61 Mn |
| Jun 30, 2018 | 9.85 Mn |
| Mar 31, 2018 | 10.35 Mn |
| Dec 31, 2017 | 7.96 Mn |
| Sep 30, 2017 | 7.62 Mn |
| Jun 30, 2017 | 7.26 Mn |
| Mar 31, 2017 | 7.05 Mn |
| Dec 31, 2016 | 7.02 Mn |
| Sep 30, 2016 | 12.11 Mn |
| Jun 30, 2016 | 12.00 Mn |
| Mar 31, 2016 | 11.65 Mn |
| Dec 31, 2015 | 11.85 Mn |
| Sep 30, 2015 | 1.95 Mn |
| Jun 30, 2015 | 1.96 Mn |
| Mar 31, 2015 | 1.85 Mn |
| Dec 31, 2014 | 1.79 Mn |
| Sep 30, 2014 | 1.93 Mn |
| Jun 30, 2014 | 2.03 Mn |
| Mar 31, 2014 | 1.94 Mn |
| Dec 31, 2013 | 1.72 Mn |
| Sep 30, 2013 | 1.74 Mn |
| Jun 30, 2013 | 1.79 Mn |
| Mar 31, 2013 | 1.88 Mn |
| Dec 31, 2012 | 1.88 Mn |
| Sep 30, 2012 | 1.32 Mn |
| Jun 30, 2012 | 1.55 Mn |
| Mar 31, 2012 | 1.39 Mn |
| Dec 31, 2011 | 1.03 Mn |
| Sep 30, 2011 | 1.15 Mn |
| Jun 30, 2011 | 1.28 Mn |
| Dec 31, 2010 | 1.95 Mn |